2024 Top Medtech Mergers and Acquisitions
In 2024, it was a busy year for the medtech industry, with several major players making significant acquisitions to strengthen their portfolios. The trend of billion-dollar sales deals continued to rise, hinting at even more M&A activity in the coming year. Let’s take a closer look at some of the biggest M&A moves of 2024:
One of the most notable transactions of the year was Johnson & Johnson’s acquisition of Shockwave Medical for a whopping $13.1 billion. This move solidified J&J’s position in the IVL market, where Shockwave’s technology uses sonic pressure waves to treat calcified arterial plaque, benefiting patients with coronary and peripheral artery diseases.
Another significant deal in 2024 was Edwards’ sale of its Critical Care business to BD for $4.2 billion. This acquisition marked a strategic shift for Edwards and allowed BD to expand its patient monitoring business segment, further enhancing its medical offerings.
Baxter also made headlines by finding a buyer for its Kidney Care business in a $3.8 billion deal with Carlyle Group. This move allowed Baxter to focus on its core areas while reducing debt and pursuing strategic initiatives.
Boston Scientific finalized its acquisition of Axonics for $3.7 billion, adding sacral neuromodulation systems to its urology portfolio. This strategic move aimed to tap into an underpenetrated market and strengthen Boston Scientific’s position in the segment.
Another significant acquisition was Johnson & Johnson’s purchase of V-Wave for $1.7 billion. This deal highlighted the company’s focus on cardiovascular implant technology and its commitment to addressing heart failure with reduced ejection fraction.
Owens & Minor expanded its offerings by acquiring Rotech Healthcare for $1.4 billion, strengthening its Patient Direct product line in home-based care services across the U.S. This acquisition opened new opportunities for Owens & Minor to provide a wider range of medical equipment to patients.
Lastly, Boston Scientific acquired Silk Road Medical for $1.18 billion, enhancing its stroke prevention technology portfolio. This deal further positioned Boston Scientific as a key player in the medtech industry, focusing on innovative solutions for patients with carotid artery disease.
Overall, 2024 was a year of significant M&A activity in the medtech sector, with key players making strategic moves to expand their offerings and solidify their positions in the market. The coming year holds the promise of even more exciting developments in the industry, with analysts predicting more significant deals on the horizon.
